FMCSA’s med board to review waiver protocol for drivers on anti-seizure medication

user-gravatar Headshot
doctor medical

The Federal Motor Carrier Safety Administration’s Medical Review Board will meet next week to discuss the criteria for which drivers on anti-seizure medications must meet in order to be cleared to drive. The board will review whether it should consider measures to change or remove the need for such drivers to seek approval from their medical examiner. 

Drivers with a history of seizures must acquire a waiver from their medical examiner in order to receive their medical certification. Waivers are granted on a case-by-case basis at the discretion of a driver’s examiner.

The MRB will also make recommendations for potential revisions to the medical examiners handbook, which is used to evaluate drivers’ medical fitness and distributed to examiners in the agency’s National Registry of Certified Medical Examiners.

The meeting was announced Sept. 13.

The MRB will meet Sept. 26-27 from 9:15 a.m. to 4:30 p.m. ET in Arlington, Virginia, at the FMCSA National Training Center. The meeting is open to the public. Comments are being accepted ahead of the meeting and are due by Sept. 20. Comments may be submitted through the Federal eRulemaking Portal.

They may also be summited via fax to 202-493-2251 or by mail to the following address: Docket Management Facility, U.S. Department of Transportation, 1200 New Jersey Ave. SE, Wed Building, Room W12-140, Washington DC, 20590. 

Oral comments may also be presented at the meeting.